From: Inflammatory markers and physical frailty: towards clinical application
Studies | Design | Population | Inflammation parameter | ||||||
---|---|---|---|---|---|---|---|---|---|
TNF-α | TNFR1 | TNFR2 | genotype | IL-6 | CRP | ||||
Schaap 2009 | Longitudinal (5y) | ≥ 70y, n = 2177 | + | + | + | N/S | - | - | |
Aguirre 2014 | Cross-sectional | ≥ 65y, n = 107 | N/S | + | N/S | N/S | - | - | |
Arts 2015 | Cross-sectional | ≥ 60y, n = 366 | N/S | N/S | N/S | N/S | - | - | |
Liu 2016 | Cross-sectional | > 60y, n = 1919 | N/S | N/S | - | N/S | + | - | |
Mekli 2016 | Cross-sectional | ≥ 50y, n = 3160 | N/S | N/S | N/S | + | N/S | N/S | |
Tay 2016 | Longitudinal (1y) | ≥ 65y, n = 99 | + | N/S | N/S | N/S | - | N/S | |
Van Epps 2016 | Cross-sectional | ≥ 60y, n = 117 | N/S | + | + | N/S | + | - | |
Langmann 2017 | Longitudinal (2y) | ≥ 65y, n = 178 | Baseline | N/S | + | + | N/S | + | + |
1y Follow-up | N/S | - | - | N/S | + | + | |||
Marcos-Pérez 2018 | Cross-sectional | ≥ 65y, n = 259 | + | N/S | + | N/S | + | + | |
Yang 2018 | Cross-sectional | ≥ 60y, n = 435 | N/S | N/S | N/S | N/S | - | - | |
Navarro-MartÃnez 2019 | Cross-sectional | ≥ 50y, n = 46 | - | N/S | N/S | N/S | + | + | |
Prince 2019 | Cross-sectional | ≥ 30y, n = 68 | N/S | N/S | N/S | + | N/S | N/S | |
Buigues 2020 | Longitudinal (1y) | ≥ 50y, n = 39 | Baseline | - | N/S | N/S | N/S | + | + |
1y Follow-up | - | N/S | N/S | N/S | + | - | |||
Furtado 2020 | Cross-sectional | ≥ 75y, n = 358 | + | N/S | N/S | N/S | + | - | |
Castellana 2021 | Longitudinal (6y) | ≥ 65y, n = 1929 | + | N/S | N/S | N/S | + | - | |
Castro-Herrera 2021 | Cross-sectional | ≥ 65y, n = 184 | - | N/S | - | N/S | - | + | |
McKechnie 2021 | Longitudinal (3y) | ≥ 70y, n = 981 | N/S | N/S | N/S | N/S | + | - | |
Teixeira-Gomes 2021 | Cross-sectional | ≥ 65y, n = 291 | N/S | N/S | N/S | N/S | + | + | |
McKechnie 2022 | Cross-sectional | ≥ 70y, n = 1399 | N/S | N/S | N/S | N/S | + | + | |
Pansarasa 2022 | Cross-sectional | ≥ 75y, n = 219 | + | N/S | N/S | N/S | + | + | |
Samson 2022 | Longitudinal (20y) | ≥ 65y, n = 144 | Baseline | N/S | N/S | N/S | N/S | + | + |
5y Follow-up | N/S | N/S | N/S | N/S | - | - |